CureVac begins CV9104 Phase 2b trial in prostate cancer patients
CV9104, the RNActive cancer vaccine, encodes antigens that are overexpressed in prostate cancer. University of Tubingen, Germany, urology department medical director and the study coordinating investigator Arnulf Stenzl
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.